IPCI had an ANDA approval that no one really new when the FDA would approve. Approval came out of nowhere and provided a surprise. This approval for IGXT is not going to be a surprise. Approval is priced in fairly closely although there will be some upside - maybe 20 -30% - which is nice for those who held. Just hope for no CRL.
You are wrong, everyone knew approval was coming that is why we were invested in it. You are right no one knew the exact timing and like IGXT they both have several key surprises to come. IGXT has 3 or possibly 4 Par drugs versus IPCI who only has one with several doses of it. Upside we will see when approval is announced and the PPS would be higher if it was a given, but it never is until it actually happens. There shouldn't be a CRL this late in the game, that would be a complete surprise. So value is not fully priced in the current PPS. I think 30% is what it may stabilize at until they announce commercialization partner when it will go up again depending on the strength of the partner. There are other considerations as the agreement with Redhill has an option for IGXT to receive higher percentages of revenues, if they reimburse Redhill for some of the development costs. Either way IGXT gets the majority of the revenues. Plus once the manufacturing facility is up and running they will make a profit producing the strips.
IPCI was able to begin selling IMMEDIATELY with 180 day exclusivity on a major dose. That makes a big difference because they are realizing revenues as we speak. When will revenues begin for the migraine film strip?????